Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Takes $5 Million Equity Stake in Its Database Partner, Ingenuity Systems

Premium

Affymetrix announced this week an equity investment in Ingenuity Systems of Mountain View, Calif., an informatics firm creating web-based products for life sciences applications.

As part of the deal, Affymetrix will add to its product offerings Ingenuity’s Pathways Analysis database product for the analysis of therapeutic networks in gene-expression array data sets. The product, containing over 1 million curated findings gathered over five years, will be offered through an annual subscription fee. Pricing details were not provided. The product is in beta release form currently and will be available in a limited release form in September, the companies said.

Affymetrix is making a $5 million equity investment in the firm, part of a Series D $7.3 million third-party financing deal for the 5-year-old company, which has taken in some $56 million in three previous rounds of venture capital investment.

The activity is the first this year for Affymetrix, which is carrying a promising investment in spinoff Perlegen Sciences, in addition to a $3 million equity investment made in December in Arcturus of Mountain View, Calif., and a small investment in GenoSpectra of Fremont, Calif., in 2001. The company previously invested in Eos Biotechnology and Orchid Biosciences.

Ingenuity already has strong ties to Affymetrix. Steve Fodor, Affymetrix chairman and CEO, is an investor, as is Alejandro Zaffaroni, who spun Affymetrix out of Affymax in 1991, and John Young, the retired CEO of Hewlett Packard and an Affymetrix board member.

Ingenuity’s previous funders include Accel Partners of Palo Alto, Calif.; Bay City Capital of San Francisco; Brookside Capital Partners, the private equity affiliate of Bain Capital of Boston; Millennium Pharmaceuticals; Morgan Stanley Dean Witter Private Equity of New York; Oracle Venture Fund of Redwood Shores, Calif.; Three Arch Partners of Portola Valley, Calif.; and Technofyn Associates, Zaffroni’s investment vehicle.

The Pathway product can generate de novo pathways for microarray researchers, said Frank Mara, Ingenuity’s senior vice president of marketing.

Also, the product is not limited to data derived from the Affymetrix platform, it will also accept tab-delineated data, he said.

—MOK

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.